[Disclosure] Celltrion (068270) to List 21,815 Additional Common Shares on November 14, 2025, Following Exercise of Stock Purchase Options (Total Value of Approx. KRW 2.14B)

Source: Financial Supervisory Service DART System / 2025-11-11

Disclosure Type: Additional Listing (Exercise of Stock Purchase Options)

💡 3-Second Summary

A total of 21,815 common shares issued through the exercise of stock purchase options will be newly listed on the KOSPI market on November 14, 2025. The aggregate value based on the issuance price stands at approximately KRW 2.14B.

📊 1. [Summary of Core Disclosure Content and Major Figures]

This filing details the issuance and additional listing schedules of new common shares resulting from the exercise of stock purchase options.

• Method of Capital Increase: Exercise of Stock Purchase Options
• Type and Number of Additional Shares to be Listed: 21,815 Registered Common Shares (Batch 167 to Batch 172)
  • Batch 167: 7,109 common shares (Issue price of KRW 79,311 per share)
  • Batch 168: 5,958 common shares (Issue price of KRW 71,999 per share)
  • Batch 169: 1,155 common shares (Issue price of KRW 156,285 per share)
  • Batch 170: 270 common shares (Issue price of KRW 156,746 per share)
  • Batch 171: 3,650 common shares (Issue price of KRW 123,606 per share)
  • Batch 172: 3,673 common shares (Issue price of KRW 128,858 per share)
• Par Value and Aggregate Value of New Shares:
  • Par Value per Share: KRW 1,000
  • Aggregate Issue Value of New Shares: KRW 2,140,079,870 (Approx. KRW 2.14B)
• Key Timelines:
  • Issuance Date: October 27, 2025
  • Dividend Accrual Date: January 01, 2025 (Fiscal year-end: Last day of December)
  • Listing Date: November 14, 2025
• Stock Code: 068270 (Standard Code: KR7068270008)

📈 2. [Expert View: What This Disclosure Means for Investors]

This filing is a regulatory announcement informing the market that the new common shares issued upon the fulfillment of stock purchase option criteria are being registered into the circulating supply.

• Addition of Outstanding Shares: Following this listing, 21,815 new common shares will enter the market’s floating supply starting November 14, 2025. Given that this volume represents a very small portion of Celltrion’s total outstanding shares, the potential dilution impact is likely to be low.
• Retroactive Dividend Accrual: The dividend accrual date for these new shares is designated as January 01, 2025. This means that these newly listed shares hold the exact same rights as the existing outstanding shares to participate in the upcoming year-end dividend for the fiscal year 2025.
• Varying Issue Prices Across Batches: The exercise prices of the stock options are structured differently across each batch, ranging from KRW 71,999 (Batch 168) to KRW 156,746 (Batch 170). Since the filing does not state any post-listing shareholding plans or subsequent transactions, investors should focus strictly on the scheduled listing dates and volumes.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has announced that an additional 21,815 common shares will be listed on November 14, following the exercise of stock purchase options. The aggregate value of the newly issued shares amounts to approximately KRW 2.14B, representing a standard administrative update that carries minor dilution risks relative to the company’s overall capital base.

While the issue prices vary from the KRW 70,000 level to the KRW 150,000 level depending on the batch, the dividend record eligibility for these shares is backdated to early 2025. This filing is designed to notify the market of the completion of option exercises and the subsequent introduction of new shares. Therefore, investors should approach this disclosure primarily as routine operational data to track the updated outstanding share count.

📢 Disclaimer & Sources

Source: This content was structured and newly written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.